Table 1.

Ongoing clinical trials of aspirin and other anti-inflammatory drugs in HIV+ patients to reduce cardiovascular risk

Drug	Phase	Randomized?	Cardiovascular and/or inflammation outcomes	Size	Status	Identifier
Aspirin
Aspirin (325 mg)	2	Y	Cardiovascular endothelial injury and thrombosis	22	Terminated	NCT00783614
			Inflammation: blood markers of inflammation (not specified further)
Aspirin (1 day 325 mg and followed by 81 mg daily) vs. clopidogrel	2	Y	Cardiovascular endothelial function	50	Recruiting	NCT02559414
			Inflammation: platelet activity, inflammation, immune activity (not specified further)
Aspirin	1 & 2	Y	Cardiovascular reactive hyperemia index	91	Completed	NCT02401269
			Inflammation: TNF-alpha, CRP, IL-6
Aspirin (81 mg) vs atorvastatin (40 mg)	2	Y	Cardiovascular carotid MR!	120	Recruiting	NCT02081638
			Inflammation: sCD14, IL-6, D-dimer, hsCRP, sCD163, sTF, others T cell activation,   (HLA-DR/CD38 coexpression), monocyte activity (CD14+, +CD16+, and CD14varCD16   +, CCR5, TF, CCR2)
Clopidogrel (75 mg) vs. aspirin (81 mg)	2	Y	Cardiovascular none	40	Recruiting	NCT02578706
			Inflammation: sCD14, monocyte activity (CD14, CD16, sCD163, cholesterol uptake),   IL-6, D-dimer, sTNFR I/II,   platelet activity (light transmission aggregometry, clot formation kinetics, thrombus   formation by Badimon chamber
Aspirin (100 and 300 mg)	2	Y	Cardiovascular brachial artery FMD	121	Completed	NCT02155985
			Inflammation: sCD14, sCD163, CD14, CD16, CD69, CD4 + CD38+, CD4 + HLA-DR+, CD8 + CD38+,   CD8 + HLA-DR+, PD-1, CTLA-4, IL-6, D-dimer, kynurenine to tryptophan ratio, serum   thromboxane b2, 11 -dehydrothromboxane
Other anti-inflammatoiy drills
Methotrexate (5, 10, and 15 mg)	2	Y	Cardiovascular brachial artery FMD, diameter, hyperemic flow velocity	200	Active, not recruiting	NCT01949116
			Inflammation: CD4 cell count, hsCRP, IL-6, sCD163, D-dimer, monocyte activity
Colchicine (0.6 mg)	2	Y	Cardiovascular coronary endothelial function, coronary artery cross-sectional artery, brachial artery FMD	102	Currently recruiting	NCT02624180
			Inflammation: hsCRP, IL-6
Pentoxifylline (400 mg)	2	Y	Cardiovascular brachial artery FMD	26	Completed	NCT00796822
			Inflammation: activated CD8 cell percentage, CD4 cell count, MCP-1, sVCAM-1, IP-10, MMP-9,   TIMP-1, PAI-1 active, hsCRP
Canakinumab (150 mg)	2	Y	Cardiovascular number of adverse events, brachial artery FMD, arterial fluorodeoxygenase (FDG)   uptake via FDG-PET/CT	110	Currently recruiting	NCT02272946
			Inflammation: hsCRP, IL-6, CD 163, D-dimer, T cell and monocyte activation, HIV reservoir size.
Anti-fibrosis drugs with anti-inflammatory properties
Losartan (50-100 mg)/raltegravir (400 mg)	4	Y	Cardiovascular carotid intima media thickness, levels of metalloproteinases and their inhibitors	48	Completed	NCT01529749
			Inflammation: lymphatic tissue fibrosis, IL-6, D-dimer, CRP, CD4, viral load, CD4/CD8 ratio
EplCTenone 50 mg	N/a	Y	Cardiovascular: coronary flow reserve measured via canliac PET, myocardial inflammation   measured by extracellular volume fraction via cardiac magnetic resonance imaging, coronary plaque   measured by coronary CTA, markers of vascular dysfunction	60	Currently recruiting	NCT02740179
			Inflammation: markers of systemic inflammation, immune activation, and fibrosis (not specified further)

Only studies that included inflammatory markers as outcomes are included.

hsCRP highly-sensitive C-reactive protein, CRP C-reactive protein, sCD14soluble CD14, sCD163 soluble CD163, IL-6 interleukin-6, FMD flow-mediated dilatation, sTNFR soluble tumor necrosis factor receptor, TNF tumor necrosis factor, MCP-1 monocyte chemotactic protein 1, sVCAM-1 soluble vascular cell adhesion molecule 1, IP-10 interferon gamma-induced protein 10, MMP-9 matrix metallopeptidase, TIMP-1 TIMP metallopeptidase inhibitor 1, PAI-1 plasminogen activator inhibitor-1, PET positron emission tomography, FDG fluorodeoxygenase, HLA-DR human leukocyte antigen-antigen D-related